These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 17157748)

  • 1. An effective treatment of severe complex regional pain syndrome type 1 in a child using high doses of intrathecal ziconotide.
    Stanton-Hicks M; Kapural L
    J Pain Symptom Manage; 2006 Dec; 32(6):509-11. PubMed ID: 17157748
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute cardiovascular toxicity of low-dose intrathecal ziconotide.
    Heifets BD; Smith SM; Leong MS
    Pain Med; 2013 Nov; 14(11):1807-9. PubMed ID: 23855951
    [No Abstract]   [Full Text] [Related]  

  • 3. [Recommendations for the management of chronic pain by intrathecal ziconotide].
    Tronnier V; Hofacker W; Ilias W; Kleinmann B; Koulousakis A; Kress HG; Likar R; Lux EA; Müller-Schwefe G; Schütze G; Uberall M
    MMW Fortschr Med; 2010 Oct; 152 Suppl 3():106-9. PubMed ID: 21595155
    [No Abstract]   [Full Text] [Related]  

  • 4. Intrathecal ziconotide for complex regional pain syndrome: seven case reports.
    Kapural L; Lokey K; Leong MS; Fiekowsky S; Stanton-Hicks M; Sapienza-Crawford AJ; Webster LR
    Pain Pract; 2009; 9(4):296-303. PubMed ID: 19500276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain.
    Wallace MS
    Expert Rev Neurother; 2006 Oct; 6(10):1423-8. PubMed ID: 17078783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Oct; 44(10):478-83. PubMed ID: 17063978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain.
    Wermeling DP; Berger JR
    Pharmacotherapy; 2006 Mar; 26(3):395-402. PubMed ID: 16503720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using ziconotide for intrathecal infusions.
    Mitchell AA; Sapienza-Crawford AJ; Hanley KL; Lokey KJ; Wells L
    Nursing; 2008 Dec; 38(12):19. PubMed ID: 19033968
    [No Abstract]   [Full Text] [Related]  

  • 9. Considerations and methodology for trialing ziconotide.
    Burton AW; Deer TR; Wallace MS; Rauck RL; Grigsby E
    Pain Physician; 2010; 13(1):23-33. PubMed ID: 20119460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain.
    Webster LR; Fakata KL; Charapata S; Fisher R; MineHart M
    Pain Med; 2008 Apr; 9(3):282-90. PubMed ID: 18366508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bolus intrathecal injection of ziconotide (Prialt®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study.
    Mohammed SI; Eldabe S; Simpson KH; Brookes M; Madzinga G; Gulve A; Baranidharan G; Radford H; Crowther T; Buchser E; Perruchoud C; Batterham AM
    Neuromodulation; 2013; 16(6):576-81; discussion 582. PubMed ID: 23205907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administering ziconotide and monitoring patients treated with ziconotide: expert opinions.
    Mitchell AA; Sapienza-Crawford AJ; Hanley KL; Lokey KJ; Wells L; McDowell GC; Stanton-Hicks M
    Pain Manag Nurs; 2013 Sep; 14(3):e84-94. PubMed ID: 23972874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trigeminal neuralgia relief with intrathecal ziconotide.
    Michiels WB; McGlthlen GL; Platt BJ; Grigsby EJ
    Clin J Pain; 2011 May; 27(4):352-4. PubMed ID: 21494183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neuropsychiatric side effects of intrathecal ziconotide].
    Ayuga-Loro F; Brocalero-Camacho Á; Quintas-López MV; Cabrera-Feria JR
    Rev Neurol; 2011 Jan; 52(1):61-3. PubMed ID: 21246497
    [No Abstract]   [Full Text] [Related]  

  • 15. Statistical evaluation of the chemical stability of ziconotide solutions during simulated intrathecal administration.
    Shields DE; Liu W; Gunning K; Montenegro R
    J Pain Symptom Manage; 2008 Jul; 36(1):e4-6. PubMed ID: 18538975
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain.
    Wallace MS; Kosek PS; Staats P; Fisher R; Schultz DM; Leong M
    Pain Med; 2008 Apr; 9(3):271-81. PubMed ID: 18366507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrathecal therapy with ziconotide: clinical experience and considerations on its use.
    Vitale V; Battelli D; Gasperoni E; Monachese N
    Minerva Anestesiol; 2008 Dec; 74(12):727-33. PubMed ID: 19034250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Low Dose Ziconotide as First-Line Intrathecal Monotherapy.
    Prusik J; Argoff C; Peng S; Pilitsis JG
    Neuromodulation; 2017 Jun; 20(4):386-391. PubMed ID: 27492135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziconotide: new drug. Limited analgesic efficacy, too many adverse effects.
    Prescrire Int; 2008 Oct; 17(97):179-82. PubMed ID: 19530373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class.
    Skov MJ; Beck JC; de Kater AW; Shopp GM
    Int J Toxicol; 2007; 26(5):411-21. PubMed ID: 17963128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.